KDM4A and neoplasm: KDM4/KDM4A inhibitors such as NCDM-32B, JmjN peptide, Purpurogallin (9bf), PKF118–310, and ML324 cause inhibition of tumor cell proliferation in breast cancer, and showcase antiproliferative activity in prostate cancer [136,137,138,139,140].